Genetic variants associated with rheumatoid arthritis patients and serotypes in European populations

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 236-241

  Ruiz Larrañaga, Otsanda ^a   Uribarri, María ^b   Alcaro, Maria C ^c   Escorza Treviño, Sergio ^b   Del Amo, Jokin ^b   Iriondo, Mikel ^a   Manzano, Carmen ^a   Migliorini, Paola ^d   Lóránd, Veronika ^e   Estonba, Andone ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Progenika Biopharma SA   (Spain)

^c Toscana Biomarkers Srl   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF PÉCS   (Hungary)

Author keywords

ACPA; Genetic association studies; Rheumatoid arthritis; SNP

Indexed keywords

CD2 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TRANSCRIPTION FACTOR REL;

ADULT; AGE; ARTICLE; BACH2 GENE; BLK GENE; CCR6 GENE; CD2 GENE; COHORT ANALYSIS; CONTROLLED STUDY; DDX6 GENE; DISEASE ASSOCIATION; EUROPEAN; GENDER; GENE; GENE IDENTIFICATION; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUNGARY; IKZF3 GENE; IL2RA GENE; IL6 GENE; IL6R GENE; IRF5 GENE; ITALY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PTPRC GENE; RACE; RASGRP1 GENE; REL GENE; RHEUMATOID ARTHRITIS; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; TLE3 GENE; TNFAIP3 GENE; AGED; FEMALE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROGROUP;

EID: 84963796079     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. ALAMANOS Y, DROSOS AA: Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005; 4: 130-6
2. VANDENBROUCKE JP, HAZEVOET HM, CATS A: Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984; 11: 158-61
3. FITZGERALD OSM M, YANNI G, ROBINSON R, BRESNIHAN B: Morphometric analysis of blood vessels in synovial membranes obtained from clinically affected and unaffected knee joints of patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 792-6
4. CASPI D, ANOUK M, GOLAN I et al.: Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum 2006; 55: 53-6
5. AVOUAC J, GOSSEC L, DOUGADOS M: Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-51
6. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative Initiative. Ann Rheum Dis 2010; 69: 1892
7. van VENRROIJ WJ, HAZES JM, VISSER H: Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383-8
8. NELL VP, MACHOLD KP, STAMM TA et al.: Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1731-6
9. NISHIMURA K, SUGYAMA D, KOGATA Y et al.: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808
10. SCHELLEKENS GA, de JONG BA, van den HOOGEN FH, van de PUTTE LB, van VENROOIJ WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-speci?c autoantibodies, J Clin Invest 1998; 101: 273-281
11. COENEN D, VERSCHUEREN P, WESTHOVENS R, BOSSUYT X: Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007; 53: 498-504
12. TROUW LA, HUIZINGA TWJ, TOES REM: Autoimmunity in rheumatoid arthritis: different antigens-common principles. Ann Rheum Dis 2013; 72: ii132-ii136
13. van der HELM-VAN MIL AH, VERPOORT KN, BREEDVELD FC, TOES RE, HIUZINGA TW: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R949-58
14. STAHL EA, RAYCHAUDHURI S, REMMERS EF et al.: Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-14
15. ZHERNAKOVA A, STAHL EA, TRYNKA G et al.: Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 2011; 7: e1002004
16. EYRE S, BOWES J, DIOGO D et al.: Highdensity genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44: 1336-40
17. PICERNO V, FERRO F, ADINOLFI A, VALENTINI E, TANI C, ALUNNO A: One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 2015; 33: 551-8
18. ZHANG J, ZHANG Y, JIN J et al.: The-1082A/G polymorphism in the Interleukin-10 gene and the risk of rheumatoid arthritis: a metaanalysis. Cytokine 2011; 56: 351-5
19. RADSTAKE TR, FRANKE B, WENINK MH et al.: The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3828-37
20. OREIRO N, FERNANDEZ-LOPEZ JC, DEL AMO J et al.: Identification of SNPs Associated with Severe Articular Damage in Patients with Rheumatoid Arthritis. Arhtritis Rheumatol 2009; 60 (Suppl. 10): 352
21. BALSA A, DEL AMO J, BLANCO F et al.: Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. Rheumatology (Oxford) 2010; 49: 458-66
22. CáLIZ R, DEL AMO J, BALSA A et al.: The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 2012; 41: 10-4
23. ROBLEDO G, DáVILA-FAJARDO CL, MáRQUEZ A et al.: Association between-174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol 2012; 31: 1486-91
24. RUYSSEN-WITRAND A, ROUANET S, COMBE B et al.: Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012; 71: 875-7
25. PURCELL S, NEALE B, TODD-BROWN K et al.: PLINK: A tool set for whole genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75
26. KURREEMAN F, LIAO K, CHIBNIK L et al.: Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multiethnic cohort derived from electronic health records. Am J Hum Genet 2011; 88: 57-69
27. PADYUKOV L, SEIELSTAD M, ONG RT et al.: A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011; 70: 259-65
28. SIGURDSSON S, PADYUKOV L, KURREEMAN FA et al.: Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007; 56: 2202-10
29. TANAKA T, NARAZAKI M, KISHIMOTO T: Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Letters 2011; 585: 3699-709
30. ENEVOLD C, BASLUND B, LINDE L et al.: Interleukin-6-receptor polymorphisms rs12083537, rs2228145, rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics 2014; 24: 401-5
31. de la RICA L, URQUIZA JM, GóMEZ-CABRERO D et al.: Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmun 2013; 41: 6-16
32. McALLISTER K, YARWOOD A, BOWES J et al.: Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum 2013; 65: 3058-62
33. MUTO A, OCHIAI K, KIMURA Y et al.: Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J 2010; 29: 4048-61
34. BARRETT JC, CLAYTON DG, CONCANNON P et al.: Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703-7
35. BARRETT JC, HANSOUL S, NICOLAE DL et al.: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62
36. HUNT KA, ZHERNAKOVA A, TURNER G et al.: Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40: 395-402
37. STONE JC: Regulation and function of the RasGRP family of Ras activators in blood cells. Genes Cancer 2011; 2: 320-34
38. COUGHLIN JJ, STANG SL, OWER NA, STONE JC: The role of RasGRPs in regulation of lymphocyte proliferation. Immunol Lett 2006; 105: 77-82
39. QU HQ, GRANT SF, BRADFIELD JP et al.: Association of RASGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies. J Med Genet 2009; 46: 553-4
40. LI H, GAN W, LU L et al.: A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans. Diabetes 2013; 62: 291-8
41. LAVU S, BOSS O, ELLIOTT PJ, LAMBERT PD: Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008; 7: 841-53
42. KURREEMAN FA, STAHL EA, OKADA Y et al.: Use of a multiethnic approach to identify rheumatoid-arthritis-susceptibility loci, 1p36 and 17q12. Am J Hum Genet 2012; 90: 524-32
43. MORGAN B, SUN L, AVITAHL N et al.: Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J 1997; 16: 2004-13
44. JOSTINS L, RIPKE S, WEERSMA RK et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24
45. LESSARD CJ, ADRIANTO I, ICE JA et al.: Identi?cation of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study. Am J Hum Genet 2012; 90: 648-60
46. SMOLEN JS, ALETAHA D: Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther 2009; 11: 204
47. XIE X, ZHANG D, CHEN JW, TIAN J, LING GH, LI F: Pharmacogenomics of biological treatment in rheumatoid arthritis. Expert Opin Biol Ther 2014; 14: 157-64
48. UMIEVIC MIRKOV M, COENEN MJ: Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics 2013; 14: 425-44